Elanco Animal Health, the premier animal-health company being spun out of Eli Lilly, is expected to begin trading on Friday.
At a price range of $20 to $23 per share, the company plans to raise up to $1.6 billion with an expected market value of around $7.7 billion. At the midpoint of its price range, the stock ELAN, +0.00% currently earns our Unattractive rating.
Elanco enters the public market with significant revenue ($2.9 billion in 2017) but falling after-tax profit (NOPAT), and negative GAAP net income. As with any health-care firm, the valuation is based less on current profitability and more on the strength of its product/vaccine portfolio (and their patents) and its success in researching and developing (or acquiring) new animal-health products.
This report aims to help investors sort through Elanco’s financial filings to understand the fundamentals and valuation of this IPO.
Profits are not as bad as they appear
Elanco earns revenue through the sale of animal-health products in categories such as flea and tick, vaccines, osteoarthritis and pain, animal only-antibiotics, probiotics, and food animal products. The company notes it is the fourth-largest animal health company in the world, based on revenue in 2017. Globally, Elanco is No. 1, No. 2, and No. 3 in medicinal, poultry, and cattle-feed additives, respectively, based on 2017 revenue.
At first glance, Elanco’s GAAP net loss ballooned from $48 million in 2016 to $311 million in 2017. NOPAT, while positive, fell, from $289 million in 2016 to $184 million in 2017.
Reported non-operating items overstated ELAN’s GAAP losses in both 2016 and 2017, which caused the greater decline in accounting results versus NOPAT. We remove both non-operating income and expense when calculating NOPAT to get at the true recurring profits of the business.
Our Robo-Analyst uncovered non-operating items in 2017, such as:
• $375 million (13% of revenue) in asset impairment, restructuring, and other special charges;
• $43 million (1% of revenue) in cost of sales due to the write-up of inventory;
• $33 million (1% of revenue) in provisional benefits due to re-measurement of deferred taxes;
• $6 million (1% of revenue) in change in total reserves.
After all adjustments, we removed a net $495 million in non-operating expenses in 2017, which resulted in positive NOPAT compared to negative GAAP net income.
With only two years of history, it’s hard to draw any firm conclusions about the long-term trend in profitability, but our adjustments show that NOPAT is falling, but at slower a rate than GAAP would indicate.
Red flags for capital allocation
As we wrote in our Long Idea on PetMed Express PETS, -0.67% we see significant growth in the animal-care market for the foreseeable future. Investors in Elanco must believe that it can capitalize on this growth while controlling costs to improve profitability. However, costly acquisitions have hampered Elanco’s ability to grow profits and create true shareholder value, even in a growing market.
Over the past three years, Elanco has spent over $6.2 billion on acquisitions. Most recently, in 2017, Elanco acquired Boehringer Ingelheim Vetmedica’s U.S. feline, canine and rabies vaccine portfolio for $882 million. In total, invested capital grew 7% in 2017, while NOPAT fell 36%. NOPAT margin fell from 10% in 2016 to 6% in 2017. This increase in invested capital, without a similar increase in profits led to Elanco’s return on invested capital (ROIC) falling from an already low 4% to 2% over the same time.
Traditional metrics obscure an expensive valuation
Figure 2 shows Elanco’s price-to-sales ratio is actually below that of its publicly traded competitors, as named in ELAN’s S-1. However, it is worth noting that each of these firms looks vastly overvalued relative to the overall market, measured by the S&P 500 SPX, +0.13% which has a price-to-sales ratio of 2.3. It’s also worth noting that from a profitability standpoint, Elanco earns the least NOPAT and has the lowest NOPAT margin of the four companies in Figure 2.
Our discounted cash flow model reveals how overvalued Elanco is
When we use our dynamic DCF model to analyze the future cash flow expectations baked into the stock price, we find that Elanco is overvalued at the midpoint of its IPO, despite what traditional metrics show.
To justify the midpoint IPO price of $21.50 a share, Elanco must immediately achieve 12% NOPAT margins (slightly below the 15% average of peers in Figure 2) and grow NOPAT by 10% compounded annually for the next 15 years. See the math behind this dynamic DCF scenario. This scenario implies immediate and drastic improvements in profitability.
Even if we assume Elanco can earn a 10% NOPAT margin (achieved in 2016), the stock still holds significant downside. If we assume the company achieves a 10% NOPAT margin and grows NOPAT by 5% compounded annually for the next decade, the stock is worth just $10/share today — a 52% downside from the IPO midpoint. See the math behind this dynamic DCF scenario.
Each of these scenarios assumes Elanco can grow revenue by 5% compounded annually, which is the estimated growth rate of the industry through 2023, according to Vetnosis, and noted in Elanco’s S-1. For comparison, Elanco’s revenue has declined about 1% compounded annually since 2015.
IPO investors get no say
Immediately following the completion of Elanco’s IPO, Eli Lilly LLY, -1.07% will own 82.3% of the outstanding stock in the company (80.2% if underwriters exercise their option to purchase additional shares). While this ownership is different from dual class structures we’ve seen in recent IPOs (Snap Inc. SNAP, +0.33% or Dropbox DBX, -2.66% for instance) the effect on voting rights is the same: IPO investors get virtually no vote.
Post-IPO, Eli Lilly will control the majority of voting power and the outcome of any actions requiring shareholder approval. Furthermore, it will be entitled to designate or nominate the number of board members proportionate to its ownership of voting shares. As long as Eli Lilly owns at least a majority of Elanco’s voting shares, it will be entitled to designate the chairman of the board and a majority of the members on the board.
While Ely Lilly has indicated that it plans to divest its interest in Elanco over time, it is under no obligation to do so. We’ve certainly seen worse corporate governance when it comes to voting rights (such as one person holding all the rights), but Elanco’s structure still give investors no say in corporate matters until Eli Lilly divests majority of its interest in the company.
Critical details found in financial filings by our robo-analyst technology
As investors focus more on fundamental research, research automation technology is needed to analyze all the critical financial details in financial filings. Below are specifics on the adjustments we make based on Robo-Analyst findings in Elanco Animal Health’s S-1:
Income statement: We made $513 million of adjustments, with a net effect of removing $495 million in non-operating expense (17% of revenue). You can see all the adjustments made to Elanco’s income statement here.
Balance sheet: We made $1.3 billion of adjustments to calculate invested capital with a net increase of $405 million. The most notable adjustment was $358 million in deferred tax assets. This adjustment represented 4% of reported net assets. You can see all the adjustments made to the balance sheet here.
Valuation: We made $515 million of adjustments with a net effect of decreasing shareholder value by $133 million. Apart from $191 million in excess cash, the largest adjustment to shareholder value was $127 million in underfunded pensions. This pension adjustment represents 2% of Elanco’s proposed market cap.
David Trainer is the CEO of New Constructs, an equity research firm that uses machine learning and natural language processing to parse corporate filings and model economic earnings. Kyle Guske II and Sam McBride are investment analysts at New Constructs. Follow them on Twitter @NewConstructs.
Also on Market Tamer…
Follow Us on Facebook